Francesca DeMartino | executive |
Albert Bourla | executive |
David Denton | executive |
Robyn Karnauskas | analyst |
Carter L. Gould | analyst |
Louise Chen | analyst |
Aamir Malik | executive |
Alexandre de Germay | executive |
Mikael Dolsten | executive |
Trung Huynh | analyst |
Terence Flynn | analyst |
Umer Raffat | analyst |
Timothy Anderson | analyst |
Andrew Baum | analyst |
Chris Boshoff | executive |
Geoffrey Meacham | analyst |
Mohit Bansal | analyst |
Steve Scala | analyst |
David Risinger | analyst |
Christopher Schott | analyst |
Rajesh Kumar | analyst |
Kerry Holford | analyst |
Chris Shibutani | analyst |
Akash Tewari | analyst |
Evan Seigerman | analyst |
Good day, everyone, and welcome to Pfizer's Fourth Quarter 2023 Earnings Conference Call. Today's call is being recorded. At this time, I would like to turn the call over to Francesca DeMartino, Chief Investor Relations Officer and Senior Vice President. Please go ahead, ma'am.
Good morning, and welcome to Pfizer's earnings call.